Literature DB >> 9102684

[Nonbacterial thrombotic endocarditis: a review of a necropsy series].

M Maté del Tío1, J Gómez Cerezo, M C Garcés Jiménez, A Mate Valdezate, C Gamallo, F J Barbado Hernández, J J Vázquez Rodríguez.   

Abstract

Nonbacterial thrombotic endocarditis (NBTE) is characterized by the deposition of thrombi on undamaged heart valves and by the increased frequency of associated arterial embolic events in patients with chronic debilitating diseases. Fifteen subjects diagnosed by necropsy of nonbacterial thrombotic endocarditis (NBTE) were studied to evaluate the general features, associated diseases, arterial embolic events, distribution and characteristics of histologic lesions. The most common underlying disease was neoplasm, which was present in 10 cases. Of these, 6 were adenocarcinomas, 3 hematological, and the remaining case was a bladder carcinoma. Other associated diseases included amyloidosis, MELAS syndrome, and sepsis. In most cases peripheral arterial embolic events were detected (9 cases). The central nervous system and the lung were involved in 7 cases (78%), heart and kidneys in 5 cases (56%), and spleen in 4 cases (44%). Other involved organs included pancreas, thyroid gland, testicles, meninges, liver and adrenal glands. The left valves were predominantly involved. The mitral valve in eight cases and the aortic valve in six cases. All cases with right involvement had the antecedent of central venous catheterization. Subendothelial fibrosis was a common histological finding which revealed the chronicity of the disease.

Entities:  

Mesh:

Year:  1997        PMID: 9102684

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  1 in total

Review 1.  Overview and Comparison of Infectious Endocarditis and Non-infectious Endocarditis: A Review of 814 Autoptic Cases.

Authors:  Rossana Bussani; Fabio DE-Giorgio; Giuliano Pesel; Lorenzo Zandonà; Gianfranco Sinagra; Simone Grassi; Alfonso Baldi; Antonio Abbate; Furio Silvestri
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.